Cardiac allograft vasculopathy: Difference between revisions
No edit summary |
|||
| Line 11: | Line 11: | ||
== [[Cardiac allograft vasculopathy historical perspective|Historical Perspective]] == | == [[Cardiac allograft vasculopathy historical perspective|Historical Perspective]] == | ||
== [[Cardiac allograft vasculopathy pathophysiology|Pathophysiology]] == | == [[Cardiac allograft vasculopathy pathophysiology|Pathophysiology]] == | ||
Revision as of 18:37, 27 July 2014
For patient information click here
|
Cardiac allograft vasculopathy Microchapters |
|
Differentiating Cardiac allograft vasculopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cardiac allograft vasculopathy On the Web |
|
American Roentgen Ray Society Images of Cardiac allograft vasculopathy |
|
Directions to Hospitals Treating Cardiac allograft vasculopathy |
|
Risk calculators and risk factors for Cardiac allograft vasculopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: CAV, cardiac transplant vasculopathy, heart transplant vasculopathy, HTx vasculopathy, transplant coronary artery disease, transplant CAD
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Cardiac allograft vasculopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrogardiogram | Chest X Ray | CT | MRI | Echocardiography | Coronary Angiography | Intravascular Ultrasound | Optical Coherence Tomography | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies